Diverticulitis Disease - Global Strategic Business Report

The global market for Diverticulitis Disease was valued at US$1.8 Billion in 2025 and is projected to reach US$3.0 Billion by 2032, growing at a CAGR of 7.4% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Diverticulitis Disease Market - Key Trends & Drivers Summarized

Why Is Diverticulitis Garnering Growing Medical Attention Worldwide?

The global diverticulitis disease market is experiencing heightened interest due to the increasing prevalence of gastrointestinal disorders and the rising demand for effective treatment solutions. Diverticulitis, a condition characterized by inflammation or infection of diverticula in the digestive tract, is becoming more common, particularly in aging populations and in regions adopting Western dietary habits. Sedentary lifestyles, low-fiber diets, and obesity are significant contributing factors to the rise in incidence. As healthcare systems globally improve diagnostic capabilities, more cases are being identified at earlier stages, leading to a broader patient base in need of medical intervention. The clinical spectrum of the disease - from uncomplicated cases to those requiring surgical procedures - has expanded the therapeutic landscape, encompassing antibiotics, anti-inflammatory medications, dietary modifications, and increasingly, advanced surgical treatments. The growing burden on healthcare resources, coupled with an aging demographic, has positioned diverticulitis as a condition of both clinical urgency and commercial opportunity, especially in developed nations.

How Are Diagnostics and Treatments Evolving in Response to Changing Demographics?

Rapid advancements in imaging technologies and diagnostic procedures are enabling more accurate detection and classification of diverticulitis, which is crucial for targeted treatment. High-resolution CT scans and colonoscopies are now standard diagnostic tools, allowing for differentiation between simple and complicated cases. On the treatment front, there is a significant shift toward non-invasive and outpatient management strategies, especially for mild to moderate cases. Antibiotic stewardship programs are encouraging physicians to limit unnecessary antibiotic use, leading to refined treatment protocols. Simultaneously, research is ongoing into novel anti-inflammatory agents and biologics that could provide targeted relief with fewer side effects. In severe cases, minimally invasive surgeries like laparoscopic resection are becoming more common, reducing hospital stays and recovery times. Nutritional therapy and fiber supplementation also play essential roles in recurrence prevention, and these aspects are being increasingly integrated into patient management plans. This confluence of better diagnostics and diversified treatments is reshaping the standard of care for diverticulitis worldwide.

Which Populations and Markets Are Driving Demand for Diverticulitis Solutions?

North America and Europe are the most mature markets for diverticulitis treatment, primarily due to high disease prevalence, established healthcare infrastructure, and strong awareness among both patients and practitioners. The United States, in particular, exhibits the highest incidence rates, attributed to dietary patterns and aging baby boomers. Europe follows closely, with countries like Germany and the UK implementing robust screening and surgical programs. In Asia-Pacific, the market is expanding rapidly due to urbanization, increasing disposable incomes, and greater access to healthcare services. Emerging markets such as India and China are witnessing a steady rise in cases, driven by shifts in diet and lifestyle. These regions are also investing in hospital infrastructure and medical training, leading to improved diagnostic and treatment capabilities. Latin America and the Middle East are nascent markets with rising awareness and increasing investments in gastrointestinal care. Across all regions, the demand for personalized and value-based care models is influencing treatment patterns and reimbursement strategies.

What Are the Key Factors Driving Market Growth?

The growth in the diverticulitis disease market is driven by several factors, including the rising prevalence of gastrointestinal disorders associated with aging populations and dietary changes, particularly in urbanized areas. Advances in diagnostic imaging technologies and increased access to colonoscopy screenings are enabling earlier and more accurate diagnoses, expanding the base of treated patients. Changes in clinical guidelines emphasizing conservative management have increased the role of pharmaceuticals, creating opportunities for drug manufacturers. Simultaneously, the expansion of minimally invasive surgical techniques has boosted the demand for surgical instruments and robotic systems. Growing patient awareness, combined with greater health literacy and demand for outpatient care, is reshaping the way diverticulitis is managed across healthcare settings. The development of new pharmaceutical agents targeting inflammation and gut microbiota modulation is also fueling innovation in the treatment pipeline. Moreover, the integration of gastrointestinal care into broader chronic disease management frameworks is reinforcing its strategic importance within global healthcare systems.

Report Scope

The report analyzes the Diverticulitis Disease market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Treatment (Medications Treatment, Surgery Treatment, Supportive Care Treatment, Antibiotics Treatment, Dietary Supplements Treatment, Other Treatments); End-Use (Specialty Centers End-Use, Hospitals End-Use, Research Centers End-Use)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Medications Treatment segment, which is expected to reach US$739.2 Million by 2032 with a CAGR of a 6.5%. The Surgery Treatment segment is also set to grow at 6.2% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $489.1 Million in 2025, and China, forecasted to grow at an impressive 11.1% CAGR to reach $630.4 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Diverticulitis Disease Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Diverticulitis Disease Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Diverticulitis Disease Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Allergan (AbbVie), AstraZeneca, Bausch Health Companies, Baxter International and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Diverticulitis Disease market report include:

• Abbott Laboratories
• Allergan (AbbVie)
• AstraZeneca
• Bausch Health Companies
• Baxter International
• Bristol-Myers Squibb
• Ferring Pharmaceuticals
• Gilead Sciences
• GlaxoSmithKline (GSK)
• Johnson & Johnson
• Medtronic
• Mylan (Viatris)
• Novartis
• Pfizer
• Roche
• Sanofi
• Sandoz (Novartis)
• Takeda Pharmaceutical
• Teva Pharmaceutical
• UCB

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.